This session will go through the main features of the call with the main objective of providing answers to any questions or doubts from researchers considering the submission of projects to I2D2.

The purpose of I2D2 program is to accelerate the process whereby new disruptive therapeutic mechanisms reach patients, by using industrial standards to evaluate the mechanisms at the incubation stage for their potential for clinical application. Although the call will remain open, the first evaluation of Expressions of Interest will be made with those submissions received until September 30th, 2017.

►Please confirm attendance at the following link: https://www.eventbrite.com/o/15117691221

Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream